California State Teachers Retirement System Buys 30,398 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

California State Teachers Retirement System grew its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 1,653.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,237 shares of the biotechnology company's stock after acquiring an additional 30,398 shares during the period. California State Teachers Retirement System owned about 0.07% of Capricor Therapeutics worth $445,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $462,000. Voloridge Investment Management LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $1,678,000. Woodline Partners LP bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $8,693,000. Two Sigma Investments LP boosted its holdings in Capricor Therapeutics by 223.6% in the 4th quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company's stock worth $1,643,000 after buying an additional 82,254 shares during the period. Finally, Rafferty Asset Management LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $1,743,000. 21.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Roth Capital assumed coverage on shares of Capricor Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $31.00 target price on the stock. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Friday. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.50.

Capricor Therapeutics Stock Down 15.5%

Capricor Therapeutics stock traded down $2.16 during trading hours on Friday, hitting $11.78. The stock had a trading volume of 3,082,158 shares, compared to its average volume of 1,823,238. The stock's 50-day moving average price is $10.72 and its 200-day moving average price is $12.73. The stock has a market capitalization of $538.08 million, a P/E ratio of -11.11 and a beta of 0.84. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The company had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. During the same period in the previous year, the firm earned ($0.31) earnings per share. On average, research analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.